Sitagliptin (Januvia™) is a new oral agent ... including T-cell activation and proliferation. Although the mechanism of action may indicate that DPP-4 inhibition is a promising treatment for ...

Opens in a new tab or window MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia ... complementary mechanisms of action, and additive efficacy is expected." ...

Both Victoza® and Januvia® were well tolerated ... Due to this glucose-dependent mechanism of action, Victoza® is associated with a low rate of hypoglycaemia. The mechanism of blood sugar ...

"Sitagliptin is one of the first drugs of class DPP-4 inhibitors introduced in India. This drug has an excellent mechanism of action and benefits a variety of patients with diabetes and continues ...